News >

Frontline Immunotherapy Combo Setbacks Strike NSCLC

Silas Inman @silasinman
Published: Friday, Jan 20, 2017

Sean Bohen, MD, PhD

Sean Bohen, MD, PhD

Bristol-Myers Squibb (BMS) and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer (NSCLC), according to statements from each of the companies.

The CheckMate-227 study continues to enroll participants, with a target enrollment goal of 2220 patients (NCT02477826). This trial is comparing platinum-based doublet chemotherapy with nivolumab monotherapy, the combination of nivolumab and ipilimumab, and the combination of nivolumab and platinum-based chemotherapy.
  1. Antonia S, Goldberg SB, Balmanoukian A, et al. Lancet Oncol. Safety and antitumor activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicenter, phase 1b study [published online February 5, 2016]. Lancet Oncol. doi:10.1016/S1470-2045(15)00544-6.
  2. Hellman MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31-41.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication